Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX in Rectal Cancer with Synchronous Metastases
NCT01674309Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Apr 2012
- Primary completion
- Jan 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and oxaliplatin in rectal cancer, sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Tumor control rate of the primary tumor and metastasis at 4 months. Started Apr 2012; status: completed.
02
Drugs
fluorouracilfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01674309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674309.